ELFBAR Responds to US Trademark Lawsuit with New Brand

Elfbar by 2FIRSTS.ai
Mar.01.2023
ELFBAR Responds to US Trademark Lawsuit with New Brand
ELFBAR responds to US trademark lawsuit by introducing new brand EBDESIGN. Sales in other markets not affected.

Editor's note: On February 28th, the disposable e-cigarette brand ELFBAR responded to reports from Global Times on the "U.S. trademark case," making their first official statement on the matter within China. ELFBAR stated in the interview that their U.S. distributor has submitted a request to the U.S. Patent and Trademark Office's Trademark Trial and Appeal Board to revoke VPR's ELF trademark registration. Additionally, ELFBAR announced the launch of a new brand called EBDESIGN, aimed at protecting the rights and interests of their users and channel partners. This announcement is in line with previous reporting from 2FIRSTS.


Global Times Online is a centrally approved news organization that was officially launched in November 2007. It is jointly sponsored by People's Daily Online and Global Times, and approved by the central network management department. It is recognized as a central level news unit that other websites can use to reprint news.


The following article features an interview with ELFBAR conducted by the Global Network's Financial Channel. The complete interview is reproduced below by 2FIRSTS.


In response to a trademark lawsuit from the US, disposable e-cigarette brand ELFBAR has launched a new brand called EBDESIGN.


The disposable e-cigarette brand ELFBAR is currently being sold in multiple countries overseas. However, a US court recently issued an order for local distributors to cease sales of ELFBAR e-cigarettes in the US, due to an interim injunction requested by VPR Brands, LP (VPR) in a trademark infringement lawsuit against ELFBAR. This claim was approved by the Southern District of Florida court.


ELFBAR swiftly appealed the temporary injunction issued by the federal circuit court and requested that the court stay the execution of the injunction during the appeals process. Additionally, one of ELFBAR's distributors submitted a request for revocation of VPR's ELF registered trademark to the US Patent and Trademark Office's Trademark Trial and Appeal Board. It is important to note that the ongoing trademark litigation in the US does not affect the registration and use of the original ELFBAR trademark in China and other markets.


ELFBAR's legal representative responded to a journalist's inquiry by stating: "Throughout the litigation process, we have been steadfast in protecting our legal rights and maintaining positive communication with our distribution partners. We will continue to vigorously defend our rights in the upcoming legal proceedings.


According to the legal representative, VPR filed a joint lawsuit against ELFBAR and several distributors in October 2022, alleging infringement of its ELF trademark and patent. In the past two years, VPR has filed lawsuits against multiple manufacturers and distributors of disposable electronic cigarettes, claiming infringement of its asserted patents. However, they often withdraw the lawsuits when the defendants raise legitimate defenses or settle the cases for relatively small amounts.


ELFBAR further stated, "Although we are disappointed with the ruling by the regional court, our legally registered design trademark featuring a unique bubble and flower pattern familiar to consumers in the US will continue to represent our equally beloved products. In addition, to protect the rights of our users and channel partners, we have decided to launch a new brand called EBDESIGN, which will adopt the same pattern design trademark and continue to provide high-quality and trustworthy products and services to the US market. The products under the EBDESIGN brand have the exact same functionality as the original brand products, and we are confident and responsible in handling this brand transition.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Appeals Court Says BAT Must Face Class Action Over Cigarette Labels
U.S. Appeals Court Says BAT Must Face Class Action Over Cigarette Labels
A U.S. appeals court ruled that British American Tobacco (BAT) must continue facing a consumer class action lawsuit over cigarette labels. The ruling allows the case to proceed but does not determine that BAT violated the law or is liable for damages. The case highlights ongoing legal risks facing major tobacco companies related to product labeling, consumer disclosures and product liability claims.
Jul.31
Data|China’s May Vape Exports Fall 10.3%; January–May Shipments Slip 0.9%
Data|China’s May Vape Exports Fall 10.3%; January–May Shipments Slip 0.9%
China’s vape-related exports fell 10.25% year on year in May 2026, marking a second consecutive monthly decline, although exports recovered modestly from April. January-May exports totaled US$4.018 billion, down 0.86% from a year earlier and broadly in line with 2025 levels.
Special Report
Jun.29
AIR Invests $20 Million in Greentank, Deepening Capital Ties Across the Vape Supply Chain
AIR Invests $20 Million in Greentank, Deepening Capital Ties Across the Vape Supply Chain
Nasdaq-listed AIR Global has invested $20 million in preferred shares of Canadian vaporization technology company Greentank, deepening a partnership established in 2023. AIR gains a board nomination right, access to new technologies, enhanced commercial terms and long-term supply assurances, while retaining an option to increase its stake. Greentank’s Quantum Chip platform powers Crown Switch and forms part of AIR’s planned U.S. PMTA dossier, linking capital investment more closely with product technology, regulatory evidence and supply-chain control.
Special Report
Jul.29
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Philip Morris Japan (PMJ) has expanded the ZYN by IQOS oral tobacco pouch portfolio in Japan with four new ZYN Strong products, adding a third intensity level alongside the existing Low and Medium ranges. The Strong series first entered selected duty-free channels in Japan on July 1, 2026, before expanding to IQOS stores, the ZYN Online Store and selected tobacco retailers from August 18. The expansion increases the Japanese ZYN by IQOS lineup from eight to 12 products.
Aug.20
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
A new expert paper in JAMA urges U.S. clinicians to include nicotine e-cigarettes in smoking-cessation discussions, citing higher quit rates than nicotine replacement therapy. It also stresses that products must deliver enough nicotine to replace cigarettes, dual use should be brief, and complete switching is the goal. 2Firsts argues the recommendations matter beyond clinics: public-health professionals should reassess relative risk, regulators should preserve sufficient product appeal for adult smokers, and manufacturers should focus on helping users quit cigarettes more sustainably.
SCIENCE
Aug.03 by 2Firsts Perspectives